How to Sequence Therapies in Mycosis Fungoides

Curr Treat Options Oncol. 2021 Sep 27;22(11):101. doi: 10.1007/s11864-021-00899-0.


Choice of therapy in mycosis fungoides is based on both patient- and lymphoma-specific factors, such as disease characteristics, comorbidities, symptoms and effect on quality of life, potential associated toxicities of therapy, response and tolerance to prior lines of therapy, and convenience and practicality. Generally, we sequence therapies from least toxic, targeted, nonimmunosuppressive to more toxic, immunosuppressive and from single agent to multiple agents, as necessary. If more toxic, immunosuppressive agents are required to alleviate disease burden or symptoms, we generally use them just long enough to control the disease, then transition to a maintenance regimen with less toxic, less immunosuppressive agents.

Keywords: CTCL; Cutaneous T cell lymphoma; Cutaneous oncology; Lymphoma; Mycosis fungoides.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Clinical Decision-Making
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Disease Management
  • Disease Susceptibility
  • Humans
  • Mycosis Fungoides / diagnosis
  • Mycosis Fungoides / etiology
  • Mycosis Fungoides / therapy*
  • Neoplasm Grading
  • Neoplasm Staging
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / etiology
  • Skin Neoplasms / therapy*
  • Treatment Outcome


  • Biomarkers, Tumor